news
Janssen submits MAA for daratumumab to EMA
10 September 2015 | By Victoria White
Daratumumab is an investigational, human anti-CD38 monoclonal antibody, for the treatment of patients with relapsed and refractory multiple myeloma...
List view / Grid view
Myeloma
news
FDA grants Priority Review to ixazomib for multiple myeloma
10 September 2015 | By Victoria White
Ixazomib is the first investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma...
news
23 drugs to be axed from the Cancer Drug Fund
7 September 2015 | By Victoria White
The announcement follows a review that found that CDF spending would rise to around £410 million for this year - an over-spend of £70m from the budget set in April 2015...
news
EC approves multiple myeloma treatment Farydak
4 September 2015 | By Victoria White
The EC has approved Farydak in combination with bortezomib and dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma...
news
FDA grants priority review for Empliciti Biologics License Application
2 September 2015 | By Victoria White
The FDA has accepted for priority review the BLA for Empliciti (elotuzumab) for the treatment of multiple myeloma as combination therapy...
news
EMA accepts MAA for multiple myeloma drug ixazomib
21 August 2015 | By Victoria White
Takeda has announced that the EMA has accepted is Marketing Authorisation Application for ixazomib for the treatment of patients with multiple myeloma...
news
Multiple myeloma treatment market value to approach $9 billion by 2021
20 August 2015 | By Victoria White
The global multiple myeloma treatment market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021, says GBI Research...
news
EMA grants accelerated assessment of MAA for Empliciti
27 July 2015 | By Victoria White
The EMA validated for review the Marketing Authorisation Application (MAA) for Empliciti for the treatment of multiple myeloma...
news
EMA grants accelerated assessment to ixazomib
27 July 2015 | By Victoria White
The CHMP of the EMA has granted an accelerated assessment to ixazomib for the treatment of patients with relapsed and/or refractory multiple myeloma...
news
Amgen submits sNDA for Kyprolis in relapsed multiple myeloma
23 July 2015 | By Victoria White
Amgen has submitted a sNDA to the US FDA for Kyprolis to seek an expanded indication for the treatment of patients with relapsed multiple myeloma...
news
Takeda submits NDA in the US for ixazomib for the treatment of multiple myeloma
15 July 2015 | By Victoria White
Takeda has submitted an NDA to the US FDA for ixazomib for the treatment of patients with relapsed and/or refractory multiple myeloma...
news
Panobinostat recommended by CHMP for EU approval to treat multiple myeloma
26 June 2015 | By Victoria White
The CHMP of the EMA have adopted a positive opinion for panobinostat capsules for the treatment of patients with multiple myeloma...
news
Oncopeptides presents clinical results from Phase I/II study of melflufen and dexamethasone in patients with relapsed and relapsed refractory multiple myeloma
17 June 2015 | By Victoria White
Oncopeptides has presented results from an ongoing study of melflufen with dexamethasone in patients with relapsed and relapsed refractory multiple myeloma...
news
Updated results from Celgene’s FIRST Study of REVLIMID presented at European Haematology Association congress
12 June 2015 | By
Celgene International has announced updated results of its pivotal Phase III FIRST trial of REVLIMID at the European Haematology Association annual congress...
news
Celyad completes 30-day safety follow-up of first patient in NKG2D Phase I trial
11 June 2015 | By Victoria White
Celyad has completed the 30-day safety follow-up of the first patient enrolled in a Phase I clinical trial evaluating the safety of NKG2D CAR T-cell therapy..
